Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study (Q43758879)

26 November 2017

Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study (English)

1 reference

26 November 2017

0 references

1 reference

I Marcil

1

1 reference

PubMed ID

11589933

26 November 2017

R S Stern

series ordinal

2

1 reference

PubMed ID

11589933

26 November 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

26 November 2017

1 reference

26 November 2017

358

1 reference

26 November 2017

1042-1045

1 reference

26 November 2017

9287

1 reference

Risk of neoplasia in renal transplant patients.

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

Cancer risk after renal transplantation in the nordic countries, 1964-1986

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

PUVA and cancer: a large-scale epidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

Risk of Cutaneous Carcinoma in Patients Treated with Oral Methoxsalen Photochemotherapy for Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

Cutaneous squamous-cell carcinoma in patients treated with PUVA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

A transformed view of cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906179-7

7 January 2021

10.1016/S0140-6736(01)06179-7

Identifiers

DOI

1 reference

26 November 2017

1 reference

PubMed ID

11589933